These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 25397524)

  • 1. Efficacy and tolerability of Etravirine in HIV-1 adult patients: Results of a large French prospective cohort.
    Allavena C; Katlama C; Cotte L; Roger PM; Delobel P; Cheret A; Duvivier C; Poizot-Martin I; Hoen B; Cabié A; Cheret A; Lahoulou R; Raffi F; Pugliese P
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19780. PubMed ID: 25397524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients.
    Allavena C; Katlama C; Cotte L; Roger PM; Delobel P; Cheret A; Duvivier C; Poizot-Martin I; Hoen B; Cabie A; Cheret A; Lahoulou R; Raffi F; Pugliese P;
    Infect Dis (Lond); 2016; 48(5):392-8. PubMed ID: 26757613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Week 48 results of a Phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected treatment-experienced adults.
    Arathoon E; Bhorat A; Silaghi R; Crauwels H; Lavreys L; Tambuyzer L; Vanveggel S; Opsomer M
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19783. PubMed ID: 25397527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study.
    Ciaffi L; Cavassini M; Genne D; Delhumeau C; Spycher Elbes R; Hill A; Wandeler G; Fehr J; Stoeckle M; Schmid P; Hirschel B; Montecucco F; Calmy A;
    Eur J Clin Invest; 2015 Jul; 45(7):720-30. PubMed ID: 25989829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
    Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rilpivirine versus etravirine validity in NNRTI-based treatment failure in Thailand.
    Teeranaipong P; Sirivichayakul S; Mekprasan S; Ruxrungtham K; Putcharoen O
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19740. PubMed ID: 25397485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy.
    Calin R; Paris L; Simon A; Peytavin G; Wirden M; Schneider L; Valantin MA; Tubiana R; Agher R; Katlama C
    Antivir Ther; 2012; 17(8):1601-4. PubMed ID: 22941896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
    Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
    Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety outcomes among treatment-experienced women and men treated with etravirine in gender, race and clinical experience.
    Hodder S; Jayaweera D; Mrus J; Ryan R; Witek J;
    AIDS Res Hum Retroviruses; 2012 Jun; 28(6):544-51. PubMed ID: 22206504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of etravirine use on hospitalization rates among highly pre-treated failing HIV-1 infected individuals between 2005 and 2011.
    Lacombe JM; Goujard C; Valantin MA; Cheret A; Lahoulou R; Girard PM; Costagliola D
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19781. PubMed ID: 25397525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis.
    Zaccarelli M; Fabbiani M; Pinnetti C; Borghi V; Giannetti A; Sterrantino G; Lorenzini P; Latini A; Loiacono L; Colafigli M; Ammassari A; D'Ettorre G; Plazzi M; Di Giambenedetto S; Antinori A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19802. PubMed ID: 25397546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection.
    Montaner J; Yeni P; Clumeck NN; Fätkenheuer G; Gatell J; Hay P; Seminari E; Peeters MP; Schöller-Gyüre M; Simonts M; Woodfall B;
    Clin Infect Dis; 2008 Oct; 47(7):969-78. PubMed ID: 18764771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
    Yazdanpanah Y; Fagard C; Descamps D; Taburet AM; Colin C; Roquebert B; Katlama C; Pialoux G; Jacomet C; Piketty C; Bollens D; Molina JM; Chêne G;
    Clin Infect Dis; 2009 Nov; 49(9):1441-9. PubMed ID: 19814627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lopinavir/ritonavir in HIV-infected patient with long-term virological failure: immunovirological response and tolerance in 121 patients of the ANRS CO8 Aproco-Copilote cohort].
    Brunet-François C; Taieb A; Masquelier B; Le Moing V; Lewden C; Dellamonica P; Cuzin L; Allavena C; Spire B; Chêne G; Raffi F;
    Med Mal Infect; 2007 Mar; 37(3):172-7. PubMed ID: 17239554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Reliquet V; Chirouze C; Allavena C; Muret P; Peytavin G; André-Garnier E; Bettinger D; Ferré V; Hoen B; Raffi F
    Antivir Ther; 2014; 19(1):117-23. PubMed ID: 24145365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinical and pharmacokinetic study of the combination of etravirine plus raltegravir in HIV patients with expanded intolerance or resistance.
    Bañón S; Moreno A; Quereda C; Gomez C; de Santiago AD; Perez-Elías MJ; Moreno S; Casado JL
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19804. PubMed ID: 25397548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
    Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
    Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients.
    Burgos J; Crespo M; Falcó V; Curran A; Navarro J; Imaz A; Domingo P; Podzamczer D; Mateo MG; Villar S; Van den Eynde E; Ribera E; Pahissa A
    J Antimicrob Chemother; 2012 Oct; 67(10):2479-86. PubMed ID: 22729925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
    Frange P; Briand N; Avettand-fenoel V; Veber F; Moshous D; Mahlaoui N; Rouzioux C; Blanche S; Chaix ML
    Pediatr Infect Dis J; 2011 Aug; 30(8):684-8. PubMed ID: 21427626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual therapy with darunavir/r plus etravirine is safe and effective as switching therapy in antiretroviral experienced HIV-patients. The BITER Study.
    Portilla J; Arazo P; Crusells J; Pérez-Martínez L; Martínez-Madrid O; Boix V; Moreno J; Navarro V; Rubio T; Reus S; Galera C; Bernal E; Jover F; Amador C; Baño D; Merino E; Saiz-de-la-Hoya P
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19803. PubMed ID: 25397547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.